|
Sun Pharmaceutical Industries announced that USFDA has granted its subsidiary an approval for an Abb |
|
|
|
|
Thursday, 09 July 2009 |
|
 These bicalutamide tablets, USP 50 milligram are therapeutically equivalent to Casodex tablets from AstraZeneca Casodex tablets have annual sales of approximately $314 million in the US.
Bicalutamide tablets are an androgen receptor inhibitor indicated for use in combination therapy with a lutenizing harmone-releasing harmone (LHRH) analog for treatment of stage D2 metastatic carcinoma of the prostate. |
